Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient	Dose level	Diagnosis	HCT regimen intensity	Time from HCT to relapse, d	Treatment before CD8⁺ T_M cell infusion	Time from relapse to CD8⁺ T_M cell infusion, d	Disease status at CD8⁺ T_M cell infusion
1	1	AML	NMA	865	Chemotherapy	236	CR2
2	1	AML	NMA	118	None	7	Active disease
3	1	AML	MA	2325	Chemotherapy	183	CR3
4	2	AML	MA	167	Chemotherapy	134	CR2
5	2	CML	MA	1531	Chemotherapy	799	CR3
6	2	CLL	NMA	437	Chemotherapy	498	Active disease
7	3	AML	NMA	59	Chemotherapy	98	Active disease
8	3	AML	RIC	214	Chemotherapy	135	Active disease
9	3	NHL	NMA	93	Chemotherapy	1106	Active disease
10	3	NHL	NMA	704	Chemotherapy	337	Active disease
11	3	AML	MA	3214	Chemotherapy	91	CR2
12	3	AML	MA	1361	Chemotherapy	418	CR3
13	3	NHL	NMA	508	Chemotherapy	855	Active disease
14	3	MM	NMA	878	Chemotherapy	3005	Active disease
15	3	ALL	RIC	303	None	125	Active disease

Patient	Dose level	Diagnosis	HCT regimen intensity	Time from HCT to relapse, d	Treatment before CD8⁺ T_M cell infusion	Time from relapse to CD8⁺ T_M cell infusion, d	Disease status at CD8⁺ T_M cell infusion
1	1	AML	NMA	865	Chemotherapy	236	CR2
2	1	AML	NMA	118	None	7	Active disease
3	1	AML	MA	2325	Chemotherapy	183	CR3
4	2	AML	MA	167	Chemotherapy	134	CR2
5	2	CML	MA	1531	Chemotherapy	799	CR3
6	2	CLL	NMA	437	Chemotherapy	498	Active disease
7	3	AML	NMA	59	Chemotherapy	98	Active disease
8	3	AML	RIC	214	Chemotherapy	135	Active disease
9	3	NHL	NMA	93	Chemotherapy	1106	Active disease
10	3	NHL	NMA	704	Chemotherapy	337	Active disease
11	3	AML	MA	3214	Chemotherapy	91	CR2
12	3	AML	MA	1361	Chemotherapy	418	CR3
13	3	NHL	NMA	508	Chemotherapy	855	Active disease
14	3	MM	NMA	878	Chemotherapy	3005	Active disease
15	3	ALL	RIC	303	None	125	Active disease

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CR2, second complete remission; CR3, third complete remission; MA, myeloablative; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NMA, non-myeloablative; RIC, reduced-intensity conditioning.

View Large

This Feature Is Available To Subscribers Only